Pachymic acid alleviates TNBS-induced intestine mucosal injury in mice
Jianying Zhou(First Affiliated Hospital Zhejiang University), Caijuan Si(Zhejiang Hospital), Wei‐Guang Wang(Nanjing University of Posts and Telecommunications), Lun Zhang(Zhejiang Sci-Tech University), Xiaoyan Zhang(Zhejiang Hospital), Guo‐Ping Jiang(Nanjing University of Posts and Telecommunications), Shan Xu(Chongqing Normal University), Qin Zhu(Zhejiang Chinese Medical University)
Cited by 0
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
|Cancer Cell|2021|232
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183